The Clinical Research Management Shared Resource (CRM) supports OHSU Knight Cancer Institute investigators in conducting translational, clinical and epidemiological research aimed at improving the lives of people and families with cancer by applying innovative strategies for cancer prevention, cancer treatment, and support of cancer survivors. The CRM provides training for new investigators, fellows, research nurses and clinical trial staff in the conduct of clinical trials. The CRM facilitates innovative and translational investigator-initiated Pilot/Phase I and small Phase II institutional protocols as part of Protocol Specific Research Support. This Shared Resource assists investigators in the preparation, conduct, and reporting of local, investigator-initiated studies. Prior to study initiation, the CRM offers investigators budget development and negotiation services as well as ongoing study account management. During conduct of a trial. Cancer Institute nurse researchers and experienced study coordinators use a team approach to provide investigators with all aspects of study coordination including safety monitoring and reporting. The CRM provides personnel management and oversight of research nurses and study coordinators.

Public Health Relevance

The Clinical Research Management Shared Resource (CRM) supports OHSU Knight Cancer Institute investigators in conducting translational, clinical and epidemiological research aimed at improving the lives of people and families with cancer by applying innovative strategies for cancer prevention, cancer treatment, and support of cancer survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-15S1
Application #
8530495
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
15
Fiscal Year
2012
Total Cost
$4,687
Indirect Cost
$1,136
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028

Showing the most recent 10 out of 277 publications